instruction
stringlengths 39
316
| response
stringlengths 121
336
| text
stringlengths 194
685
|
|---|---|---|
Can you inform me about the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd)? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: Can you inform me about the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd)?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
I’m interested in the median PFS of Daratumumab+Lenalidomide+Dexamethasone (DRd). | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: I’m interested in the median PFS of Daratumumab+Lenalidomide+Dexamethasone (DRd).
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
Could you tell me the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd)? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: Could you tell me the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd)?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
What is the median PFS rate for Daratumumab+Lenalidomide+Dexamethasone (DRd)? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: What is the median PFS rate for Daratumumab+Lenalidomide+Dexamethasone (DRd)?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
What is the median PFS rate in patients who have undergone Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: What is the median PFS rate in patients who have undergone Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
What’s the median PFS rate for patients receiving Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: What’s the median PFS rate for patients receiving Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
Could you provide the median Progression-Free Survival rate for patients treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
What is the median rate of Progression-Free Survival in patients who have been treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
Can you inform me about the median PFS rate in patients that were treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
What is the median PFS rate for patients that have undergone Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: What is the median PFS rate for patients that have undergone Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
Could you tell me the median Progression-Free Survival rate for patients who received Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
What’s the median rate of PFS in patients treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: What’s the median rate of PFS in patients treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
Can you share the median Progression-Free Survival rate in patients who have received Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of 45.8 months, with a 95% CI of (34.1, NE). |
Can you tell me the median PFS for Lenalidomide+Dexamethasone (Rd)? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: Can you tell me the median PFS for Lenalidomide+Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
What’s the median PFS associated with Lenalidomide+Dexamethasone (Rd)? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: What’s the median PFS associated with Lenalidomide+Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
Could you provide the median PFS of Lenalidomide+Dexamethasone (Rd)? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: Could you provide the median PFS of Lenalidomide+Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
I’d like to know the median PFS of Lenalidomide+Dexamethasone (Rd). | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: I’d like to know the median PFS of Lenalidomide+Dexamethasone (Rd).
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
Do you have information on the median PFS of Lenalidomide+Dexamethasone (Rd)? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: Do you have information on the median PFS of Lenalidomide+Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
What is the median progression-free survival (PFS) for Lenalidomide+Dexamethasone (Rd)? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: What is the median progression-free survival (PFS) for Lenalidomide+Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
Can you inform me about the median PFS for Lenalidomide+Dexamethasone (Rd)? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: Can you inform me about the median PFS for Lenalidomide+Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
I’m interested in the median PFS of Lenalidomide+Dexamethasone (Rd). | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: I’m interested in the median PFS of Lenalidomide+Dexamethasone (Rd).
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
Could you tell me the median PFS for Lenalidomide+Dexamethasone (Rd)? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: Could you tell me the median PFS for Lenalidomide+Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
What is the median PFS rate for Lenalidomide+Dexamethasone (Rd)? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: What is the median PFS rate for Lenalidomide+Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
What is the median PFS rate in patients who have undergone Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: What is the median PFS rate in patients who have undergone Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
What’s the median PFS rate for patients receiving Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: What’s the median PFS rate for patients receiving Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
Could you provide the median Progression-Free Survival rate for patients treated with Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
What is the median rate of Progression-Free Survival in patients who have been treated with Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
Can you inform me about the median PFS rate in patients that were treated with Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
What is the median PFS rate for patients that have undergone Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: What is the median PFS rate for patients that have undergone Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
Could you tell me the median Progression-Free Survival rate for patients who received Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
What’s the median rate of PFS in patients treated with Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: What’s the median rate of PFS in patients treated with Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
Can you share the median Progression-Free Survival rate in patients who have received Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 17.5 months, with a 95% CI of (13.9, 20.8). |
Can you tell me the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd)? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: Can you tell me the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd)?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
What’s the median PFS associated with Daratumumab+Bortezomib+Dexamethasone (DVd)? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: What’s the median PFS associated with Daratumumab+Bortezomib+Dexamethasone (DVd)?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
Could you provide the median PFS of Daratumumab+Bortezomib+Dexamethasone (DVd)? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: Could you provide the median PFS of Daratumumab+Bortezomib+Dexamethasone (DVd)?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
I’d like to know the median PFS of Daratumumab+Bortezomib+Dexamethasone (DVd). | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: I’d like to know the median PFS of Daratumumab+Bortezomib+Dexamethasone (DVd).
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
Do you have information on the median PFS of Daratumumab+Bortezomib+Dexamethasone (DVd)? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: Do you have information on the median PFS of Daratumumab+Bortezomib+Dexamethasone (DVd)?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
What is the median progression-free survival (PFS) for Daratumumab+Bortezomib+Dexamethasone (DVd)? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: What is the median progression-free survival (PFS) for Daratumumab+Bortezomib+Dexamethasone (DVd)?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
Can you inform me about the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd)? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: Can you inform me about the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd)?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
I’m interested in the median PFS of Daratumumab+Bortezomib+Dexamethasone (DVd). | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: I’m interested in the median PFS of Daratumumab+Bortezomib+Dexamethasone (DVd).
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
Could you tell me the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd)? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: Could you tell me the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd)?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
What is the median PFS rate for Daratumumab+Bortezomib+Dexamethasone (DVd)? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: What is the median PFS rate for Daratumumab+Bortezomib+Dexamethasone (DVd)?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Daratumumab+Bortezomib+Dexamethasone (DVd) regimen? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Daratumumab+Bortezomib+Dexamethasone (DVd) regimen?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
What is the median PFS rate in patients who have undergone Daratumumab+Bortezomib+Dexamethasone (DVd) regimen? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: What is the median PFS rate in patients who have undergone Daratumumab+Bortezomib+Dexamethasone (DVd) regimen?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Daratumumab+Bortezomib+Dexamethasone (DVd) regimen? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Daratumumab+Bortezomib+Dexamethasone (DVd) regimen?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
What’s the median PFS rate for patients receiving Daratumumab+Bortezomib+Dexamethasone (DVd) regimen? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: What’s the median PFS rate for patients receiving Daratumumab+Bortezomib+Dexamethasone (DVd) regimen?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
Could you provide the median Progression-Free Survival rate for patients treated with Daratumumab+Bortezomib+Dexamethasone (DVd) regimen? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Daratumumab+Bortezomib+Dexamethasone (DVd) regimen?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
What is the median rate of Progression-Free Survival in patients who have been treated with Daratumumab+Bortezomib+Dexamethasone (DVd) regimen? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Daratumumab+Bortezomib+Dexamethasone (DVd) regimen?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
Can you inform me about the median PFS rate in patients that were treated with Daratumumab+Bortezomib+Dexamethasone (DVd) regimen? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Daratumumab+Bortezomib+Dexamethasone (DVd) regimen?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
What is the median PFS rate for patients that have undergone Daratumumab+Bortezomib+Dexamethasone (DVd) regimen? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: What is the median PFS rate for patients that have undergone Daratumumab+Bortezomib+Dexamethasone (DVd) regimen?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
Could you tell me the median Progression-Free Survival rate for patients who received Daratumumab+Bortezomib+Dexamethasone (DVd) regimen? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Daratumumab+Bortezomib+Dexamethasone (DVd) regimen?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
What’s the median rate of PFS in patients treated with Daratumumab+Bortezomib+Dexamethasone (DVd) regimen? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: What’s the median rate of PFS in patients treated with Daratumumab+Bortezomib+Dexamethasone (DVd) regimen?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
Can you share the median Progression-Free Survival rate in patients who have received Daratumumab+Bortezomib+Dexamethasone (DVd) regimen? | Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Daratumumab+Bortezomib+Dexamethasone (DVd) regimen?
### Response: Patients treated with the Daratumumab+Bortezomib+Dexamethasone (DVd) have a median Progression-Free Survival (PFS) rate of 16.7 months, with a 95% CI of (12.3, NE). |
Can you tell me the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP)? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Can you tell me the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP)?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What’s the median PFS associated with Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP)? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What’s the median PFS associated with Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP)?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Could you provide the median PFS of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP)? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Could you provide the median PFS of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP)?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
I’d like to know the median PFS of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP). | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: I’d like to know the median PFS of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP).
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Do you have information on the median PFS of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP)? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Do you have information on the median PFS of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP)?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What is the median progression-free survival (PFS) for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP)? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What is the median progression-free survival (PFS) for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP)?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Can you inform me about the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP)? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP)?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
I’m interested in the median PFS of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP). | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: I’m interested in the median PFS of Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP).
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Could you tell me the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP)? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Could you tell me the median PFS for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP)?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What is the median PFS rate for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP)? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP)?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What is the median Progression-Free Survival (PFS) rate in patients treated with Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What is the median PFS rate in patients who have undergone Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What is the median PFS rate in patients who have undergone Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What’s the median PFS rate for patients receiving Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What’s the median PFS rate for patients receiving Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Could you provide the median Progression-Free Survival rate for patients treated with Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What is the median rate of Progression-Free Survival in patients who have been treated with Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Can you inform me about the median PFS rate in patients that were treated with Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What is the median PFS rate for patients that have undergone Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for patients that have undergone Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Could you tell me the median Progression-Free Survival rate for patients who received Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What’s the median rate of PFS in patients treated with Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What’s the median rate of PFS in patients treated with Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Can you share the median Progression-Free Survival rate in patients who have received Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen? | Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) regimen?
### Response: Patients treated with the Daratumumab And Velcade (Bortezomib) Melphalan-Prednisone (D-VMP) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Can you tell me the median PFS for Velcade Melphalan-Prednisone (VMP)? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: Can you tell me the median PFS for Velcade Melphalan-Prednisone (VMP)?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
What’s the median PFS associated with Velcade Melphalan-Prednisone (VMP)? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: What’s the median PFS associated with Velcade Melphalan-Prednisone (VMP)?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
Could you provide the median PFS of Velcade Melphalan-Prednisone (VMP)? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: Could you provide the median PFS of Velcade Melphalan-Prednisone (VMP)?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
I’d like to know the median PFS of Velcade Melphalan-Prednisone (VMP). | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: I’d like to know the median PFS of Velcade Melphalan-Prednisone (VMP).
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
Do you have information on the median PFS of Velcade Melphalan-Prednisone (VMP)? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: Do you have information on the median PFS of Velcade Melphalan-Prednisone (VMP)?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
What is the median progression-free survival (PFS) for Velcade Melphalan-Prednisone (VMP)? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: What is the median progression-free survival (PFS) for Velcade Melphalan-Prednisone (VMP)?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
Can you inform me about the median PFS for Velcade Melphalan-Prednisone (VMP)? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: Can you inform me about the median PFS for Velcade Melphalan-Prednisone (VMP)?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
I’m interested in the median PFS of Velcade Melphalan-Prednisone (VMP). | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: I’m interested in the median PFS of Velcade Melphalan-Prednisone (VMP).
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
Could you tell me the median PFS for Velcade Melphalan-Prednisone (VMP)? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: Could you tell me the median PFS for Velcade Melphalan-Prednisone (VMP)?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
What is the median PFS rate for Velcade Melphalan-Prednisone (VMP)? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: What is the median PFS rate for Velcade Melphalan-Prednisone (VMP)?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Velcade Melphalan-Prednisone (VMP) regimen? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Velcade Melphalan-Prednisone (VMP) regimen?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
What is the median PFS rate in patients who have undergone Velcade Melphalan-Prednisone (VMP) regimen? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: What is the median PFS rate in patients who have undergone Velcade Melphalan-Prednisone (VMP) regimen?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Velcade Melphalan-Prednisone (VMP) regimen? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Velcade Melphalan-Prednisone (VMP) regimen?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
What’s the median PFS rate for patients receiving Velcade Melphalan-Prednisone (VMP) regimen? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: What’s the median PFS rate for patients receiving Velcade Melphalan-Prednisone (VMP) regimen?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
Could you provide the median Progression-Free Survival rate for patients treated with Velcade Melphalan-Prednisone (VMP) regimen? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Velcade Melphalan-Prednisone (VMP) regimen?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
What is the median rate of Progression-Free Survival in patients who have been treated with Velcade Melphalan-Prednisone (VMP) regimen? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Velcade Melphalan-Prednisone (VMP) regimen?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
Can you inform me about the median PFS rate in patients that were treated with Velcade Melphalan-Prednisone (VMP) regimen? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Velcade Melphalan-Prednisone (VMP) regimen?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
What is the median PFS rate for patients that have undergone Velcade Melphalan-Prednisone (VMP) regimen? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: What is the median PFS rate for patients that have undergone Velcade Melphalan-Prednisone (VMP) regimen?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
Could you tell me the median Progression-Free Survival rate for patients who received Velcade Melphalan-Prednisone (VMP) regimen? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Velcade Melphalan-Prednisone (VMP) regimen?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
What’s the median rate of PFS in patients treated with Velcade Melphalan-Prednisone (VMP) regimen? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: What’s the median rate of PFS in patients treated with Velcade Melphalan-Prednisone (VMP) regimen?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
Can you share the median Progression-Free Survival rate in patients who have received Velcade Melphalan-Prednisone (VMP) regimen? | Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Velcade Melphalan-Prednisone (VMP) regimen?
### Response: Patients treated with the Velcade Melphalan-Prednisone (VMP) have a median Progression-Free Survival (PFS) rate of 18.1 months, with a 95% CI of (16.5, 19.9). |
Can you tell me the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd)? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Can you tell me the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd)?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Subsets and Splits